BRIEF—WuXi expands collaboration with Texas-based Aravive Biologics

Shanghai-based WuXi Biologics has expanded a collaboration with Texas, USA-based Aravive Biologics following the firm’s US regulatory filing for oncology candidate AVB-S6-500.

WuXi chief executive Chris Chen said: “We look forward to collaborating with Aravive over the coming years on further molecules in their pipeline.”

Aravive chairman Ray Tabibiazar said: "We look forward to building on our relationship with WuXi Biologics as we move forward with our plans to advance AVB-S6-500 into clinical testing and expand the Aravive pipeline over the coming years."